Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Benzinga Pro’s 5 Stocks To Watch Today

Courtesy of Benzinga.

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!

Tesla Inc (NASDAQ: TSLA) stock traded higher by 0.8 percent early Wednesday morning. The company is scheduled to report its fourth quarter results after market close and is expected to lose $3.12 per share on revenue of $3.28 billion.

Perry Ellis International, Inc. (NASDAQ: PERY) gained more than 10 percent after the apparel company confirmed an acquisition offer from George Feldenkreis, the company’s founder who was recently ousted as executive chairman but still controls more than 11 percent of all outstanding shares. He’s joining forces with Fortress Investment Group, a private equity firm, to take Perry Ellis private.

Snap Inc (NYSE: SNAP) gained more than 20 percent in reaction to an encouraging earnings report. The social media company said after Tuesday’s close it lost 13 cents per share in the fourth quarter on revenue of $285.693 million. Wall Street analysts were excepting the company to lose 16 cents per share on revenue of $253.01 million.

Credit Suisse AG – VelocityShares Daily Inverse VIX Short Term ETN (NYSE: XIV) was trading lower by more than 16 percent ahead of Wednesday’s open after plummeting 92 percent Tuesday. The inverse volatility ETN was Benzinga’s most-searched ticker throughout Tuesday’s trading session after Credit Suisse said it will be liquidating the instrument.

Verastem Inc (NASDAQ: VSTM) gained more than 8 percent after the biopharmaceutical company that focuses on developing drugs for patients with cancer announced an update to its lead product candidate, duvelisib. Versatem said it has submitted a New Drug Application to the U.S. Food and Drug Administration for full approval of duvelisib, which is a first-in-class oral dual inhibitor for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Related Links:

20 Stocks Moving In Wednesday’s Pre-Market Session

A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street; Dow Futures Down 160 Points

Posted-In: News Pre-Market Outlook Trading Ideas


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!